Dosage Form Solutions will have a strong presence at this year’s AAPS, leveraging the additional technologies and capabilities brought by our 2013 acquisitions. – Encap Drug Delivery and more recently, Bend Research.
Morristown, N.J. (PRWEB) November 05, 2013
Capsugel scientists will present and discuss innovative drug delivery technologies that can efficiently address some of the industry’s most pressing formulation and development challenges during the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place in San Antonio, Texas, from November 10-14.
“Dosage Form Solutions will have a strong presence at this year’s AAPS, leveraging the additional technologies and capabilities brought by our 2013 acquisitions – Encap Drug Delivery and more recently, Bend Research. Our scientists will present and discuss various aspects of our premier bioavailability enhancement and modified and targeted release technology platforms along with illustrative case studies,” said Amit Patel, President of Dosage Form Solutions at Capsugel. “The DFS range of technologies allows us to quickly choose the optimal approach with which to meet a client’s target product profile and accelerate formulation and development timelines.”
Capsugel DFS experts will lead two symposia and present 19 posters covering bioenhancement, modified and targeted drug release, and specialized healthcare applications, including abuse deterrence, highly potent API formulations, and inhalation technologies. Click here to review Capsugel’s Hard Capsule and the DFS scientific presence and here to schedule a meeting with the R&D teams from Bend Research and Capsugel.
Sven Stegemann, PhD, Director for Pharmaceutical Business Development at Capsugel will chair a symposium on patient-centric drug delivery addressing the diversity of today’s patient populations, which is challenging the traditional 'one-size-fits-all' approach to drug formulation and development.
"More patient-centric formulations and drug products for the young, the elderly, and those with swallowing difficulties are urgently needed," said Dr. Stegemann. Capsugel will preview its patient-centric, easy-to-open Coni-Snap® sprinkle capsules developed by company scientists to improve adherence to treatment regimens. The new Coni-Snap® sprinkle capsule is expected to be available in 2014.
To learn more about Capsugel’s innovative portfolio of hard capsules, including its Coni-Snap sprinkle capsules, and to meet with formulation scientists with its Dosage Forms Solutions group, visit Capsugel’s booth (#2012) and Bend Research’s booth (#533).
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions (DFS) business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit http://www.capsugel.com.
# # #
For media inquiries, contact Christina Chnaider at 610-680-6214 or christina.chnaider(at)capsugel(dot)com